Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Molecular Autism
Published in: Molecular Autism 1/2017

Open Access 01-12-2017 | Research

Early development of infants with neurofibromatosis type 1: a case series

Authors: Anna May Kolesnik, Emily Jane Harrison Jones, Shruti Garg, Jonathan Green, Tony Charman, Mark Henry Johnson, the EDEN-BASIS Team+

Published in: Molecular Autism | Issue 1/2017

Login to get access

Abstract

Background

Prospective studies of infants at familial risk for autism spectrum disorder (ASD) have yielded insights into the earliest signs of the disorder but represent heterogeneous samples of unclear aetiology. Complementing this approach by studying cohorts of infants with monogenic syndromes associated with high rates of ASD offers the opportunity to elucidate the factors that lead to ASD.

Methods

We present the first report from a prospective study of ten 10-month-old infants with neurofibromatosis type 1 (NF1), a monogenic disorder with high prevalence of ASD or ASD symptomatology. We compared data from infants with NF1 to a large cohort of infants at familial risk for ASD, separated by outcome at age 3 of ASD (n = 34), atypical development (n = 44), or typical development (n = 89), and low-risk controls (n = 75). Domains assessed at 10 months by parent report and examiner observation include cognitive and adaptive function, sensory processing, social engagement, and temperament.

Results

Infants with NF1 showed striking impairments in motor functioning relative to low-risk infants; this pattern was seen in infants with later ASD from the familial cohort (HR-ASD). Both infants with NF1 and the HR-ASD group showed communication delays relative to low-risk infants.

Conclusions

Ten-month-old infants with NF1 show a range of developmental difficulties that were particularly striking in motor and communication domains. As with HR-ASD infants, social skills at this age were not notably impaired. This is some of the first information on early neurodevelopment in NF1. Strong inferences are limited by the sample size, but the findings suggest implications for early comparative developmental science and highlight motor functioning as an important domain to inform the development of relevant animal models. The findings have clinical implications in indicating an important focus for early surveillance and remediation in this early diagnosed genetic disorder.
Appendix
Available only for authorised users
Literature
1.
Baird G, et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet. 2006;368(9531):210–5.PubMedCrossRef
2.
Jones EJH, Gliga T, Bedford R, Charman T, Johnson MH. Developmental pathways to autism: a review of prospective studies of infants at risk. Neurosci Biobehav Rev. 2014;39:1–33.PubMedPubMedCentralCrossRef
3.
Ozonoff S, et al. Diagnostic stability in young children at risk for autism spectrum disorder: a baby siblings research consortium study. J Child Psychol Psychiatry. 2015;56(9):988–98.PubMedPubMedCentralCrossRef
4.
Sanders SJ. First glimpses of the neurobiology of autism spectrum disorder. Curr Opin Genet Dev. 2015;33:80–92.CrossRef
5.
Hornig M, et al. Prenatal fever and autism risk. Mol Psychiatry. 2017;(00):1-8.
6.
Johnson MH, Jones EJH, Gliga T. Brain adaptation and alternative developmental trajectories. Dev Psychopathol. 2015;27(2):425–42.PubMedCrossRef
7.
Loth E, Spooren W, Murphy DG. New treatment targets for autism spectrum disorders: EU-AIMS. Lancet Psychiatry. 2014;1(6):413–5.PubMedCrossRef
8.
Estes A, et al. Behavioral, cognitive, and adaptive development in infants with autism spectrum disorder in the first 2 years of life. J Neurodev Disord. 2015;7(1):1–10.CrossRef
9.
Clifford SM, Hudry K, Elsabbagh M, Charman T, Johnson MH. Temperament in the first 2 years of life in infants at high-risk for autism spectrum disorders. J Autism Dev Disord. 2013;43(3):673–86.PubMedCrossRef
10.
Flanagan JE, Landa R, Bhat A, Bauman M. Head lag in infants at risk for autism: a preliminary study. Am J Occup Ther. 2012;66(5):577–85.PubMedCrossRef
11.
Nickel LR, Thatcher AR, Keller F, Wozniak RH, Iverson JM. Posture development in infants at heightened vs. low risk for autism spectrum disorders. Infancy Off J Int Soc Infant Stud. 2013;18(5):639–61.
12.
Libertus K, Sheperd KA, Ross SW, Landa RJ. Limited fine motor and grasping skills in 6-month-old infants at high risk for autism. Child Dev. 2014;85(6):2218–31.PubMedPubMedCentral
13.
Ozonoff S, et al. A prospective study of the emergence of early behavioral signs of autism. J Am Acad Child Adolesc Psychiatry. Mar. 2010;49(3):256–266.e2.PubMedPubMedCentral
14.
Jones EJH, et al. Reduced engagement with social stimuli in 6-month-old infants with later autism spectrum disorder: a longitudinal prospective study of infants at high familial risk. J Neurodev Disord. 2016;8:7.PubMedPubMedCentralCrossRef
15.
16.
17.
Macari SL, Campbell D, Gengoux GW, Saulnier CA, Klin AJ, Chawarska K. Predicting developmental status from 12 to 24 months in infants at risk for autism spectrum disorder: a preliminary report. J Autism Dev Disord. 2012;42(12):2636–47.PubMedPubMedCentralCrossRef
18.
Ozonoff S, Macari S, Young GS, Goldring S, Thompson M, Rogers SJ. Atypical object exploration at 12 months of age is associated with autism in a prospective sample. Autism Int J Res Pract. 2008;12(5):457–72.CrossRef
19.
Zwaigenbaum L, Bryson S, Rogers T, Roberts W, Brian J, Szatmari P. Behavioral manifestations of autism in the first year of life. Int J Dev Neurosci Off J Int Soc Dev Neurosci. 2005;23(2–3):143–52.CrossRef
20.
Gammer I, et al. Behavioural markers for autism in infancy: scores on the Autism Observational Scale for infants in a prospective study of at-risk siblings. Infant Behav. Dev. 2015;38:107–15.PubMedPubMedCentralCrossRef
21.
Richards C, Jones C, Groves L, Moss J, Oliver C. Prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2015;2(10):909–16.PubMedCrossRef
22.
23.
Evans DG, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A(2):327–32.PubMedCrossRef
24.
Lehtonen A, et al. Cognition in children with neurofibromatosis type 1: data from a population-based study. Dev Med Child Neurol. 2015;57(7):645–51.PubMedCrossRef
25.
Garg S, et al. Neurofibromatosis type 1 and autism spectrum disorder. Pediatrics. 2013;132(6):e1642–8.PubMedCrossRef
26.
Garg S, et al. Autism spectrum disorder profile in neurofibromatosis type I. J Autism Dev Disord. 2015;45(6):1649–57.PubMedCrossRef
27.
Costa RM, et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature. 2002;415(6871):526–30.PubMedCrossRef
28.
Molosh AI, et al. Social learning and amygdala disruptions in Nf1 mice are rescued by blocking p21-activated kinase. Nat Neurosci. 2014;17(11):1583–90.PubMedPubMedCentralCrossRef
29.
Diggs-Andrews KA, Tokuda K, Izumi Y, Zorumski CF, Wozniak DF, Gutmann DH. Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice. Ann Neurol. 2013;73(2):309–15.PubMedCrossRef
30.
31.
Li W, et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol CB. 2005;15(21):1961–7.PubMedCrossRef
32.
Omrani A, et al. HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1. Mol Psychiatry. 2015;20(11):1311–21.PubMedPubMedCentralCrossRef
33.
van der Vaart T, et al. Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial. Lancet Neurol. 2013;12(11):1076–83.PubMedCrossRef
34.
35.
36.
Office of Medical Applications of Research, National Institutes of Health. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988;45(5):575–8.
37.
Mullen EM. Mullen scales of early learning. MN: AGS Circle Pines; 1995.
38.
Sparrow SS. Vineland Adaptive Behavior Scales. In: Kreutzer JS, DeLuca J, Caplan B, editors. Encyclopedia of clinical neuropsychology. NY: Springer; 2011. p. 2618–21.CrossRef
39.
Bryson SE, Zwaigenbaum L. Autism Observation Scale for Infants. In: Patel VB, Preedy VR, Martin CR, editors. Comprehensive guide to autism. New York: Springer; 2014. p. 299–310.CrossRef
40.
Brian J, et al. Clinical assessment of autism in high-risk 18-month-olds. Autism. 2008;12(5):433–56.PubMedCrossRef
41.
Bryson SE, Zwaigenbaum L, McDermott C, Rombough V, Brian J. The Autism Observation Scale for Infants: scale development and reliability data. J Autism Dev Disord. 2008;38(4):731–8.PubMedCrossRef
42.
Putnam SP, Helbig AL, Gartstein MA, Rothbart MK, Leerkes E. Development and assessment of short and very short forms of the infant behavior questionnaire-revised. J Pers Assess. 2014;96(4):445–58.PubMedCrossRef
43.
Hogan AL, Caravella KE, Ezell J, Rague L, Hills K, Roberts JE. Autism spectrum disorder symptoms in infants with fragile X syndrome: a prospective case series. J Autism Dev Disord. 2017;47(6):1628–44.PubMedPubMedCentralCrossRef
44.
Gartstein MA, Rothbart MK. Studying infant temperament via the revised infant behavior questionnaire. Infant Behav Dev. 2003;26(1):64–86.CrossRef
45.
Dunn W, Daniels DB. Initial development of the infant/toddler sensory profile. J Early Interv. 2002;25(1):27–41.CrossRef
46.
Ozonoff S, et al. A prospective study of the emergence of early behavioral signs of autism. J Am Acad Child Adolesc Psychiatry. 2010;49(3):256–266.e2.PubMedPubMedCentral
47.
Klein-Tasman BP, et al. Cognitive and psychosocial phenotype of young children with neurofibromatosis-1. J Int Neuropsychol Soc JINS. 2014;20(1):88–98.PubMedCrossRef
48.
Brei NG, Klein-Tasman BP, Schwarz GN, Casnar CL. Language in young children with neurofibromatosis-1: relations to functional communication, attention, and social functioning. Res Dev Disabil. 2014;35(10):2495–504.PubMedCrossRef
49.
Lorenzo J, Barton B, Acosta MT, North K. Mental, motor, and language development of toddlers with neurofibromatosis type 1. J Pediatr. 2011;158(4):660–5.PubMedCrossRef
50.
Hummelvoll G, Antonsen KM. Young adults’ experience of living with neurofibromatosis type 1. J Genet Couns. 2013;22(2):188–99.PubMedCrossRef
51.
Pride NA, Crawford H, Payne JM, North KN. Social functioning in adults with neurofibromatosis type 1. Res Dev Disabil. 2013;34(10):3393–9.PubMedCrossRef
52.
Ferner RE, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44(2):81.PubMedCrossRef
53.
Kolanczyk M, et al. Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet. 2007;16(8):874–86.PubMedCrossRef
54.
Sullivan K, et al. NF1 is a critical regulator of muscle development and metabolism. Hum Mol Genet. 2014;23(5):1250–9.PubMedCrossRef
55.
McDonald NM, et al. Early autism symptoms in infants with tuberous sclerosis complex. Autism Res Off J Int Soc Autism Res. 2017. (e-print ahead of publication). doi:10.​1002/​aur.​1846.
Metadata
Title
Early development of infants with neurofibromatosis type 1: a case series
Authors
Anna May Kolesnik
Emily Jane Harrison Jones
Shruti Garg
Jonathan Green
Tony Charman
Mark Henry Johnson
the EDEN-BASIS Team+
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Molecular Autism / Issue 1/2017
Electronic ISSN: 2040-2392
DOI
https://doi.org/10.1186/s13229-017-0178-0

Other articles of this Issue 1/2017

Molecular Autism 1/2017 Go to the issue

Research

Neural synchronization deficits linked to cortical hyper-excitability and auditory hypersensitivity in fragile X syndrome

Research

Identification of autism-related MECP2 mutations by whole-exome sequencing and functional validation

Research

Exaggerated CpH methylation in the autism-affected brain

Research

Prospective investigation of FOXP1 syndrome

Research

Etiological influences on the stability of autistic traits from childhood to early adulthood: evidence from a twin study

Short report

Interrelationship between insistence on sameness, effortful control and anxiety in adolescents and young adults with autism spectrum disorder (ASD)